FDA grants expanded approval for Merck’s lung cancer drug Keytruda (MRK)
IvelinRadkov The FDA has granted expanded approval for Merck’s (NYSE:MRK) oncology drug Keytruda in the treatment of non-small cell lung cancer, or NSCLC. Keytruda, also known as pembrolizumab, was approved as a neoadjuvant and…
